ArticleCancers2021
Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Oestrogen receptor phosphorylation profiles and in silico PAM50 subtyping reflect sexual dimorphism in breast cancer.The journal of pathology. Clinical research · 2026Article
- The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.Breast cancer research : BCR · 2026Article
- Article
- Global, Regional, and National Burden of Male Breast Cancer, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.Cancer medicine · 2025Article
- HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients.Scientific reports · 2025Article
- Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.Breast cancer (Tokyo, Japan) · 2024Article
- Exploring the One Health Paradigm in Male Breast Cancer.Journal of mammary gland biology and neoplasia · 2024Review
- Gender-Specific Genetic Predisposition to Breast Cancer:Cancers · 2024Review
- HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy.Cancers · 2024Article
- Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome.International journal of breast cancer · 2024Review
- Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
Male breast cancer (MBC) is a rare and understudied disease compared with female BC. About 15% of MBCs are associated with germline mutation in BC susceptibility genes, mainly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.